Data On Off-Label Targeted Cancer Drugs More Plentiful Than Helpful -AHRQ
Executive Summary
Evidence within compendia to support the off-label use of targeted cancer therapies varies widely and is rapidly evolving, making it difficult to draw solid conclusions regarding safety and efficacy, according to a draft technology assessment report released for comment by the Agency for Healthcare Research and Quality